Royalty Pharma has created a rapidly growing company within the biopharmaceutical industry through the acquisition of revenue producing intellectual property – principally, royalty interests in marketed and late stage development biopharmaceutical products. Royalty Pharma does not discover, develop, manufacture or market products. Instead, the Company provides liquidity to royalty owners and assumes the future risks and rewards of ownership. Royalty Pharma has been working with research institutions, inventors and biotechnology & pharmaceutical companies since 1996, and now owns royalty interests in thirty-eight approved and marketed biopharmaceutical products and two products in clinical trials and/or under review with the United States Food and Drug Administration (“FDA”) and/or the European Medicines Agency ("EMA").

© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.